Inflectra

Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Understanding and using biosimilarsBiosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.
Biosimilars and interchangeable biologics: News to watchBiosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Biosimilars for cancer treatment on the U.S. horizonCancer treatments are expected to dominate much of the first wave of biosimilars in the U.S. This Q&A discussion looks at some of the questions pharmacists have about use of biosimilars in cancer treatment.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
Biosimilar approvals deemed “too slow”While FDA’s approval last week of infliximab-dyyb (Inflectra, Celltrion and Hospira), a biosimilar to Remicade (Janssen Biotech) for rheumatoid arthritis, Chron’s disease and other conditions is positive, FDA’s approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM).